Myasthenia Gravis

Peptide Vaccine Ready For Testing In Humans

Published in Vaccine Weekly, July 4th, 2001

by N.R. Saltmarsh, staff medical writer - A new report in Experimental Biology and Medicine describes the potential for a vaccine against myasthenia gravis in humans, following its success against a similar disease in animals.

The peptide vaccine was most effective when conjugated to diphtheria toxin (DT) with alum as adjuvant and is now ready for trial in humans, reported J.L. McAnally and colleagues at the University of Alabama, Birmingham.

"Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by interference with neuromuscular transmission by auto-antibodies against the nicotinic acetylcholine receptor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry